{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:55:31Z","timestamp":1790704531540,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.autrev.2019.102352","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T19:41:04Z","timestamp":1563306064000},"page":"102352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antiphospholipid syndrome's genetic and epigenetic aspects"],"prefix":"10.1016","volume":"18","author":[{"given":"Annamaria","family":"Iuliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2969-6649","authenticated-orcid":false,"given":"Gian Domenico","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2019.102352_bb0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.autrev.2016.01.005","article-title":"Genetic aspects of the antiphospholipid syndrome: An update","volume":"15","author":"Sebastiani","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102352_bb0010","first-page":"475","article-title":"HLA antigens in Italian patients with systemic lupus erythematosus: evidence for the association of DQw2 with the autoantibody response to extractable nuclear antigens","volume":"9","author":"Lulli","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.102352_bb0015","first-page":"223","article-title":"IgG anti-cardiolipin antibodies in murine lupus","volume":"78","author":"Gharavi","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2019.102352_bb0020","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4049\/jimmunol.149.3.1063","article-title":"Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome","volume":"149","author":"Hashimoto","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102352_bb0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1006\/jaut.1993.1023","article-title":"Antibodies to cardiolipin in normal C57BL\/6J mice: induction by estrogen but not dihydrotestosterone","volume":"6","author":"Ansar Ahmed","year":"1993","journal-title":"J Autoimm"},{"key":"10.1016\/j.autrev.2019.102352_bb0030","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2694::AID-IMMU2694>3.0.CO;2-#","article-title":"Multigenic control of lupus-associated antiphospholipid syndrome in a model of (NZW x BXSB)F1 mice","volume":"28","author":"Ida","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2019.102352_bb0035","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/art.40195","article-title":"Major Histocompatibility Complex Class II Alleles InfluenceInduction of Pathogenic Antiphospholipid Antibodies in a Mouse Model of Thrombosis","volume":"69","author":"Papalardo","year":"2017","journal-title":"Arthitis Rheumatol"},{"key":"10.1016\/j.autrev.2019.102352_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.autrev.2017.10.014","article-title":"Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses","volume":"17","author":"Islam","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102352_bb0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.1980.tb03814.x","article-title":"Familial association of the lupus anticoagulant","volume":"45","author":"Exner","year":"1980","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2019.102352_bb0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jcp.42.5.495","article-title":"Familial occurrence of the antiphospholipid syndrome","volume":"42","author":"Matthey","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.autrev.2019.102352_bb0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF02115779","article-title":"Different clinical manifestations of a lupus anticoagulant in the same family","volume":"69","author":"Jolidon","year":"1991","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.autrev.2019.102352_bb0060","first-page":"1393","article-title":"A family study of the antiphospholipid syndrome associated with other autoimmune diseases","volume":"19","author":"Dagenais","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2019.102352_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(82)91726-3","article-title":"Lupus anticoagulant: a familial observation","volume":"2","author":"Rouget","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2019.102352_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2141.1987.tb02358.x","article-title":"Familial lupus anticoagulants","volume":"67","author":"Mackie","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2019.102352_bb0075","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/art.1780360413","article-title":"Different manifestations of the antiphospholipid antibody syndrome in a family with systemic lupus erythematosus","volume":"36","author":"May","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102352_bb0080","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3892\/mmr.2017.6217","article-title":"A genetic risk factor for thrombophilia in a Han Chinese family","volume":"15","author":"Guoping","year":"2017","journal-title":"Mol Med Rep"},{"issue":"12","key":"10.1016\/j.autrev.2019.102352_bb0085","first-page":"1768","article-title":"Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus","volume":"15","author":"Wilson","year":"1988","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2019.102352_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/096120339300200203","article-title":"HLA antigens and complement C4 allotypes in patients with chronic biologically false positive (CBFP) seroreactions for syphilis: a follow-up study of SLE patients and CBFP reactors","volume":"2","author":"Stephansson","year":"1993","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2019.102352_bb0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00005792-199307000-00003","article-title":"Clinical expression of systemic lupus erythematosus in patients with C4A deficiency","volume":"72","author":"M","year":"1993","journal-title":"Medicine (Baltimore)."},{"issue":"12","key":"10.1016\/j.autrev.2019.102352_bb0100","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/art.1780311216","article-title":"Tincani et al. HLA-DR antigens and anticardiolipin antibodies in northern Italian systemic lupus erythematosus patients","volume":"31","author":"Savi","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2019.102352_bb0105","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/anr.1780321222","article-title":"HLA-DR antigens and anticardiolipin antibodies in patients with systemic lupus erythematosus","volume":"32","author":"McHugh","year":"1989","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2019.102352_bb0110","first-page":"425","article-title":"HLA-DR antigens and anticardiolipin antibodies","volume":"8","author":"McNeil","year":"1990","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2019.102352_bb0115","first-page":"95","article-title":"MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study","volume":"13","author":"Hartung","year":"1992","journal-title":"SLE Study Group. Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2019.102352_bb0120","first-page":"423","article-title":"HLA-DRB1 alleles and beta 2 glycoprotein I-dependent anticardiolipin antibodies in Japanese patients with systemic lupus erythematosus","volume":"16","author":"Hashimoto","year":"1998","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2019.102352_bb0125","first-page":"1684","article-title":"Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival","volume":"20","author":"Gulko","year":"1993","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102352_bb0130","first-page":"42","article-title":"HLA-DP genotyping in patients with systemic lupus erythematosus: correlations with autoantibody subsets","volume":"19","author":"Galeazzi","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2019.102352_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/096120330000900109","article-title":"HLA class II associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus","volume":"9","author":"Galeazzi","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.102352_bb0140","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1191\/0961203303lu402oa","article-title":"European Concerted Action on Immunogenetics of SLE. HLA-DPB1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus","volume":"12","author":"Sebastiani","year":"2003","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2019.102352_bb0145","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/art.1780350119","article-title":"Major histocompatibility complex associations with primary antiphospholipid syndrome","volume":"35","author":"Asherson","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2019.102352_bb0150","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.51.12.1301","article-title":"Autoantibodies in chronic arthritis of childhood: relations with each other and with histocompatibility antigens","volume":"51","author":"Malleson","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102352_bb0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/08820130802116117","article-title":"Anti-cofactor autoantibodies in systemic lupus erythematosus: prevalence, clinical and HLA class II asociations","volume":"37","author":"Sebastiani","year":"2008","journal-title":"Immunol Inv"},{"key":"10.1016\/j.autrev.2019.102352_bb0160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/1529-0131(199902)42:2<268::AID-ANR8>3.0.CO;2-K","article-title":"Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups","volume":"42","author":"Arnett","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102352_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/rheumatology\/40.1.31","article-title":"HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients","volume":"40","author":"Caliz","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2019.102352_bb0170","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/1529-0131(200003)43:3<683::AID-ANR26>3.0.CO;2-2","article-title":"Association of antiphosphatidylserine\/prothrombin autoantibodies witfa HLA class II genes","volume":"43","author":"Bertolaccini","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102352_bb0175","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2018.01.027","article-title":"Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102352_bb0180","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.27345","article-title":"IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor","volume":"62","author":"Fredi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102352_bb0185","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/art.24701","article-title":"Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome","volume":"60","author":"Yin","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102352_bb0190","article-title":"Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2locus","volume":"3","author":"Ochoa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.102352_bb0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.smim.2006.03.008","article-title":"Role of PTPN22 in type 1 diabetes and other autoimmune diseases","volume":"18","author":"Bottini","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2019.102352_bb0200","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1744-313X.2011.01038.x","article-title":"The PTPN22*R620W polymorphism does not confer genetic susceptibility to antiphospholipid syndrome in the Spanish population","volume":"38","author":"Castro-Marrero","year":"2011","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.autrev.2019.102352_bb0205","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/1529-0131(199908)42:8<1655::AID-ANR14>3.0.CO;2-B","article-title":"A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome","volume":"42","author":"Hirose","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102352_bb0210","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0961203312440348","article-title":"Association between the valine\/leucine247 polymorphism of \u03b22-glycoprotein I and susceptibility to anti-phospholipid syndrome: a meta-analysis","volume":"21","author":"Lee","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.102352_bb0215","first-page":"926","article-title":"Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?","volume":"31","author":"Berman","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.102352_bb0220","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/09537104.2013.830709","article-title":"Atypical erythrocytes and platelets in a patient with a pro-thrombin mutation","volume":"25","author":"Pretorius","year":"2014","journal-title":"Platelets"},{"key":"10.1016\/j.autrev.2019.102352_bb0225","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00001721-200112000-00012","article-title":"Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome","volume":"12","author":"Ames","year":"2001","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.autrev.2019.102352_bb0230","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2018.07.006","article-title":"The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome","volume":"169","author":"Plas\u00edn-Rodr\u00edgueza","year":"2018","journal-title":"Thrombosis Res"},{"key":"10.1016\/j.autrev.2019.102352_bb0235","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.hemonc.2018.03.005","article-title":"The relation between protein Z polymorphism and the risk of thrombosis in Egyptian patients with antiphospholipid syndrome","volume":"11","author":"Yomna","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.autrev.2019.102352_bb0240","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/0961203315615222","article-title":"SR. BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus","volume":"25","author":"Picceli","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.102352_bb0245","first-page":"926","article-title":"Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?","volume":"31","author":"Berman","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.102352_bb0250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/09537104.2013.830709","article-title":"Atypical erythrocytes and platelets in a patient with a pro-thrombin mutation","volume":"25","author":"Pretorius","year":"2014","journal-title":"Platelets"},{"key":"10.1016\/j.autrev.2019.102352_bb0255","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00001721-200112000-00012","article-title":"Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome","volume":"12","author":"Ames","year":"2001","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.autrev.2019.102352_bb0260","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/638129","article-title":"The pathogenicity of anti-\u03b22GP1-IgG autoantibodies depends on Fc glycosylation","author":"Fickentscher","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2019.102352_bb0265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1538-7836.2011.04301.x","article-title":"Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I","volume":"9","author":"Passam","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.autrev.2019.102352_bb0270","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.autrev.2014.10.010","article-title":"Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases","volume":"14","author":"Mackern-Oberti","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102352_bb0275","doi-asserted-by":"crossref","DOI":"10.1038\/srep31375","article-title":"Atherothrombosis-associated microRNAs in Antiphospholipidsyndrome and Systemic Lupus Erythematosus patients","volume":"6","author":"P\u00e9rez-S\u00e1nchez","year":"2016","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.autrev.2019.102352_bb0280","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2015.05.008","article-title":"Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy","volume":"14","author":"Zhang","year":"2015","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2019.102352_bb0285","series-title":"Handbook of systemic autoimmune diseases","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1571-5078(08)00406-6","article-title":"Genetic aspects of the Antiphospholipid Syndrome: HLA Associations","volume":"10","author":"Sebastiani","year":"2009"},{"key":"10.1016\/j.autrev.2019.102352_bb0290","series-title":"Chapter of the book \u201cAntiphospholipid Syndrome in Systemic Autoimmune Diseases\u201d","first-page":"69","article-title":"Genetic and epigenetic aspects of antiphospholipid syndrome. What we knew, what we know","author":"Iuliano","year":"2016"},{"issue":"10","key":"10.1016\/j.autrev.2019.102352_bb0295","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/0961203309106918","article-title":"Immunogenetic studies on systemic lupus erythematosus","volume":"18","author":"Sebastiani","year":"2009","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2019.102352_bb0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4081\/reumatismo.2012.7","article-title":"MicroRNAs in autoimmune rheumatic diseases","volume":"64","author":"Galeazzi","year":"2012","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2019.102352_bb0305","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1177\/0961203318777112","article-title":"Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset","volume":"27","author":"Sebastiani","year":"2018","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.autrev.2019.102352_bb0310","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2019.102352_bb0315","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.autrev.2008.07.009","article-title":"Treatment of rheumatic diseases in patients with HCV and HIV infection","volume":"8","author":"Galeazzi","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2019.102352_bb0320","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/039463201002300313","article-title":"A study of Adenosine-Deaminase genetic polymorphism in rheumatoid arthritis","volume":"23","author":"Sebastiani","year":"2010","journal-title":"Int J Immunopathol Pharmacol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219301521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219301521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:15:51Z","timestamp":1761599751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219301521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1568997219301521"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102352","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid syndrome's genetic and epigenetic aspects","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102352"}}